Results 121 to 130 of about 19,474 (223)

Clinical History and Burden of Gaucher Disease Type 3: A Cross‐Sectional Multinational Study

JIMD Reports, Volume 67, Issue 6, November 2026.
ABSTRACT Gaucher disease Type 3 (GD3) is a rare genetic neurodegenerative disorder, characterized by heterogeneity in symptom burden, disease severity, and progression. There is limited evidence on the burden of GD3. This retrospective, cross‐sectional study estimated the burden of illness associated with GD3 using descriptive analyses of clinician ...
Eugen Mengel, Sinziana Stanescu, Alessio Di Fonzo, Aimee Donald, Tanya Collin‐Histed, Laurence Djatche, Idaira Rodriguez Santana, Jagan Mohan Palli, Maria Gabriela Perichon, Ruth Pulikottil‐Jacob, Fatih S. Ezgu   +10 more
wiley   +1 more source

Expression of Disialoganglioside (GD2) in Neuroblastic Tumors: A Prognostic Value for Patients Treated With Anti-GD2 Immunotherapy

, 2017
Neuroblastoma, a malignant neoplasm of the sympathetic nervous system, is one of the most aggressive pediatric cancers. Patients with stage IV high-risk neuroblastoma receive an intensive multimodal therapy ending with an immunotherapy based on a ...
Mona Beaunoyer, Michel Peuchmaur, Martine Cordeau, Pierre Teira, Sonia Cournoyer, Herve Sartelet, Tatjana Terzic, Sabine Herblot, Michel Duval   +8 more
core   +1 more source

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma

Journal of Hematology & Oncology, 2020
Background The cure rate for metastatic osteosarcoma has not substantially improved over the past decades. Clinical trials of anti-HER2 trastuzumab or anti-GD2 dinutuximab for metastatic or refractory osteosarcoma were not successful, and neither was ...
Jeong A. Park, Nai-Kong V. Cheung
doaj   +1 more source

Copper chelation redirects neutrophil function to enhance anti-GD2 antibody therapy in neuroblastoma

Nature Communications
Anti-disialoganglioside (GD2) antibody therapy has provided clinical benefit to patients with neuroblastoma however efficacy is likely impaired by the immunosuppressive tumor microenvironment. We have previously defined a link between intratumoral copper
J. Rouaen, Antonietta Salerno, T. Shai-Hee, J. Murray, Giulia Castrogiovanni, Charlotte McHenry, T. Jue, Vu Pham, J. Bell, Ensieh Poursani, E. Valli, Riccardo Cazzoli, Naomi Damstra, D. Nelson, Kofi L. P. Stevens, Jonathan Chee, I. Slapetova, Maria A. Kasherman, Renée Whan, Francis Lin, Blake J. Cochran, N. Tedla, Feyza Colakoglu Veli, A. Yuksel, C. Mayoh, F. Saletta, D. Mercatelli, Tatyana Chtanova, A. Kulasinghe, D. Catchpoole, Giuseppe Cirillo, M. Biro, Holger N. Lode, Fabio Luciani, M. Haber, Juliet C. Gray, T. Trahair, O. Vittorio   +37 more
semanticscholar   +1 more source

Autologous anti-GD2 CAR T cells efficiently target primary human glioblastoma

npj Precision Oncology
Glioblastoma (GBM) remains a deadly tumor. Treatment with chemo-radiotherapy and corticosteroids is known to impair the functionality of lymphocytes, potentially compromising the development of autologous CAR T cell therapies.
C. Chiavelli, M. Prapa, G. Rovesti, Marco Silingardi, G. Neri, G. Pugliese, L. Trudu, M. Dall'Ora, G. Golinelli, G. Grisendi, J. Vinet, M. Bestagno, C. Spano, R. Papapietro, R. Depenni, Katia Di Emidio, A. Pasetto, Daniela Nascimento Silva, A. Feletti, S. Berlucchi, Corrado Iaccarino, G. Pavesi, Massimo Dominici   +22 more
semanticscholar   +1 more source

An Australian Narrative Review of Adoptive Cellular Therapies in Malignancy: Expanding Indications, Referral Pathways and Safety Beyond Specialist Centres

Medical Journal of Australia, Volume 224, Issue 11, November 2026.
ABSTRACT Adoptive cellular therapies (ACT), including tumour‐infiltrating lymphocyte (TIL), T‐cell receptor‐engineered T (TCR‐T) cell and chimeric antigen receptor T‐cell (CAR‐T) therapies, represent an evolving class of immunotherapies with established efficacy in selected haematological malignancies and emerging applications in solid tumours ...
Sarah Childs, David Ma, Anthony Rodrigues, Jennifer Massey, Rasha Cosman, Venessa Chin, Laila Girgis, James Lynam, Peter Lau, Barbara Withers, Anthony M. Joshua, Ben Tran, Jayesh Desai, Simon J. Harrison, John Moore, Jia Liu   +15 more
wiley   +1 more source

A novel approach to guide GD2-targeted therapy in pediatric tumors by PET and [64Cu]Cu-NOTA-ch14.18/CHO

Theranostics
Background: The tumor-associated disialoganglioside GD2 is a bona fide immunotherapy target in neuroblastoma and other childhood tumors, including Ewing sarcoma and osteosarcoma.
Nils F. Trautwein, J. Schwenck, C. Seitz, Ferdinand Seith, Eduardo Calderón, Sebastian von Beschwitz, Stephan Singer, Gerald Reischl, R. Handgretinger, J. Schäfer, Peter Lang, B. Pichler, J. Schulte, C. la Fougère, H. Dittmann   +14 more
semanticscholar   +1 more source

Nanoprobe‐Enabled Precision Imaging and Panoramic Boundary Delineation in Retinoblastoma

Cancer Innovation, Volume 5, Issue 5, October 2026.
This review highlights that nanoprobe‐enabled multimodal imaging, combined with targeted probe design and AI‐assisted analysis, significantly enhances the precise visualization and boundary delineation of retinoblastoma. It further outlines key challenges and directions for translating high‐performance imaging nanoprobes into clinical practice.
Xuefei He, Precious Amarachi Ikwuagwu, Wenjing Pang, Aomen Chen, Lingchao Xiang, Feng Chen, Chen Xu, Aiguo Wu   +7 more
wiley   +1 more source

Targeted therapies in retinoblastoma: GD2-directed immunotherapy following autologous stem cell transplantation and evaluation of alternative target B7-H3

Cancer Immunology and Immunotherapy
Background GD2-directed immunotherapy is highly effective in the treatment of high-risk neuroblastoma (NB), and might be an interesting target also in other high-risk tumors.
Thomas Eichholz, F. Heubach, Anne-Marie Arendt, C. Seitz, I. Brecht, M. Ebinger, T. Flaadt, D. Süsskind, Lisa Richter, Isabel Hülsenbeck, L. Zerweck, S. Göricke, Frank Paulsen, Frank Dombrowski, Christian Flotho, S. Schönberger, P. Ketteler, J. Schulte, P. Lang   +18 more
semanticscholar   +1 more source

Graph attention network‐driven single‐cell omics analysis reveals how B4GALNT1‐mediated glycosylation remodelling of the ferroptosis–pyroptosis network promotes drug resistance in hepatocellular carcinoma

Clinical and Translational Medicine, Volume 16, Issue 10, October 2026.
Summary: B4GALNT1‐driven ganglioside/raft remodelling links ferroptosis suppression with restricted caspase‐1/GSDMD signalling during sorafenib resistance. Note: Schematic summary of the proposed B4GALNT1–ganglioside–lipid‐raft axis linking ferroptosis protection, restricted caspase‐1/GSDMD‐associated membrane permeabilisation, and sorafenib resistance.
Lihan Bie, Biao Xu, Haitao Shen, Shuwen Ren, Xiaoyang Yao, Zhouhong Xiang, Zheng Xu   +6 more
wiley   +1 more source